The short answer
CBD may add to ropinirole-related sleepiness, so discuss it with your prescriber before use. Prescription CBD also affects an enzyme involved in clearing ropinirole, but the size of any ropinirole-level change is unknown.
What this answer covers
Purified oral prescription cannabidiol provides most of the evidence; nonprescription CBD formulations and other routes are not assumed equivalent.
- Supplement or preparation
- Cannabidiol
- Medication ingredient
- ropinirole
Why sleepiness is the main concern
Ropinirole can cause marked drowsiness or sudden sleep episodes. Prescription CBD can also cause sedation, and its label warns that other medicines causing sedation can worsen it. That supports caution about the combination even though its added risk has not been measured.
Drug metabolism is a separate uncertainty
In a small study, high-dose prescription CBD increased exposure to caffeine, used as a test of CYP1A2 activity. Ropinirole uses that enzyme too, but the caffeine result cannot tell us how much, if at all, your ropinirole level would change.
Product and dose matter to the review
Most evidence comes from purified oral CBD at prescription doses. A small Parkinson disease study reported frequent sleepiness but had no comparison group. Show your clinician the CBD dose, other ingredients and route; a different product may produce a different exposure.
If sleepiness develops
Contact your prescriber promptly for new marked daytime sleepiness or falling asleep during ordinary activities. Do not drive or use machinery if this occurs. Ropinirole can cause sleep episodes even without a warning feeling of drowsiness; the treating team should decide how to change treatment.
Evidence and practical considerations
Side effects & toxicity
A conditional sleepiness precaution is supported by the separate drug labels and CBD tolerability evidence; exact combined risk and ropinirole exposure changes are unmeasured.
- Exact scope
- Purified oral prescription cannabidiol provides most of the evidence; nonprescription CBD formulations and other routes are not assumed equivalent. with Oral immediate-release ropinirole; hydrochloride salt expressed as equivalent free base in the inspected label.
- Medication form and route
- oral ropinirole; supplement preparation and route described in scope
- Timing or duration
- No exact-pair safe duration or protective spacing interval established.
What remains uncertain
- Evidence is largely from prescription oral CBD and an enzyme probe. Accessible Parkinson-study abstract does not confirm a ropinirole subgroup or isolate a medication interaction.
Factors that may matter: other sedating medicines; existing daytime sleepiness; prescription-dose oral CBD.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral immediate-release ropinirole tablets for Parkinson disease or primary restless legs syndrome.
Ropinirole can cause somnolence, sudden sleep episodes and orthostatic hypotension. Concomitant sedating medicines or alcohol can increase sleepiness risk. CYP1A2 is its major metabolic enzyme; inhibitors and inducers may alter clearance. Ciprofloxacin increased exposure, whereas theophylline did not. Cigarette smokers had lower dose-normalized exposure than nonsmokers in a small RLS comparison.
How this applies: Exact oral ropinirole risk and metabolic context; section 11 justifies hydrochloride-to-free-base active-moiety identity only.
None of these ten supplement pairs is directly tested in this label. Cigarette smoking is not interchangeable with oral cannabis or isolated CBD; ciprofloxacin results are not caffeine results. No extended-release kinetic equivalence assumed.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients receiving prescription purified cannabidiol oral solution.
Somnolence and sedation occur and can be potentiated by other CNS depressants. Cannabidiol is a weak CYP1A2 inhibitor; some substrate exposures may increase.
How this applies: Supports a conditional combined-sleepiness precaution with a medicine independently known to cause somnolence; not a numerical pair-risk estimate.
No ropinirole study and no equivalence to every nonprescription CBD product, concentration or route. Epilepsy trials had other medicines, especially clobazam, affecting sedation.
Source 3: phase 1 fixed-sequence pharmacokinetic study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 16 healthy adults enrolled; nine completed.
Caffeine AUC increased 95% and peak concentration 15% in the primary analysis. Six participants discontinued for raised liver transaminases.
How this applies: Supports CYP1A2 inhibition as a possible additional mechanism; numerical effect cannot be transferred to ropinirole.
High-dose pharmaceutical CBD and a caffeine probe; no ropinirole, and small completion sample.
Source 4: open-label dose-escalation study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 13 treated participants with Parkinson disease.
Somnolence was reported by 69%; most adverse events were mild, none serious, and three participants discontinued for intolerance. Symptom improvements were uncontrolled.
How this applies: Parkinson disease tolerability context, not an isolated or quantified ropinirole-CBD interaction.
No comparator; exact concomitant ropinirole exposure could not be verified from accessible original abstract. Full-text access failed.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources inspected and exact current claim adjudicated; no clinical review asserted. | |
| Research summary published |
Article revision: 14c3c1ef284b6783
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.